| PROJECT MANAGEMENT |
 | | |
 |
| | | TUESDAY, FEBRUARY 26th: MAIN CONFERENCE DAY ONE |
| | | 4. Executing Project/Portfolio Management |
| |
| | 2:00 | Opening Remarks from the Track Chair
Mark Horn, Director, Finance and R&D Portfolio Management, WYETH |
| | | |
| |
| | 2:10 | | Pipeline Prioritization: Optimizing Value from Early Stage Portfolios | | • | Approaches to defining and measuring risk-adjusted value in
early stage development | • • | Linking project management to portfolio management Bridging the gap between commercial and R&D |
|
| | | |
| | | Jeffrey S. Handen, Ph.D., Director, R&D Portfolio Management, MERCK & CO, INC |
| | | |
| |
| | 2:50 | Lightning Process Evaluation: An Accelerated Process Evaluation Technique The initial process improvement evaluation step is critical to selecting the right processes on which to focus. Lightning Evaluation simplifies and accelerates the selection of processes to work on and provides immediate, actionable improvement actions across the board. The approach also includes a benchmarking component that allows a
company to compare its most critical processes to others inside and outside the industry. Graeme Currie, PhD, Vice President, Clinical Operations, PDL BIOPHARMA Dave Zuckerman, President, CUSTOMIZED IMPROVEMENT STRATEGIES LLC |
|
| | | |
| |
| | 3:30 | | Featured Exhibit Hall Activity: CTC's February Frenzy- "Nothing but Net(working)" Event
This is the final chance of the day to walk around the exhibit hall and talk
to as many exhibitors as possible to earn "Nothing but Net(wo meeting is
just like shooting a basket- get 3 points (very relevant), 2 points, or 1 point.
The more ‘shots' you take, the more points you get |
|
| |
| | 4:10 | Reinventing Drug Development - Cross Functional Teams and the Learn and Confirm Paradigm
While we are working with increasingly innovative drug candidates
and ever more complex disease targets, several disturbing trends have
emerged in our industry. The probability of success is decreasing, and
cycle times are increasing as the costs of research skyrocket. Wyeth has
fundamentally changed the way it approaches drug development, and in so doing,
reinvented itself. The introduction of the Learn and Confirm paradigm and the
use of truly cross functional teams will be presented as one way to address the
challenges that we are all confronting. |
| | | |
| | | William Jacobson , PhD, Director, Project Management, WYETH PHARMACEUTICALS |
| | | |
| |
| | 4:50 | Risk Mitigation through Process Development
Recent government regulatory interest in several areas of clinical research
has made it critical for sponsors to have processes in place to ensure
compliance with external and internal guidelines.
| | • | Clinical trial registries and registers
| | • | Investigator Initiated Trials
| | • | Medicare coverage in budget dvpt
| | • | Oversight of third party vendors |
|
| | | Tracy Mastro, Director, HURON CONSULTING SERVICES, LLC |
| |
| |
| | | |
